Skip to main content

Synlogic, Inc. (SYBX)

NASDAQ: SYBX · IEX Real-Time Price · USD
3.20 0.02 (0.63%)
Sep 24, 2021 12:38 PM EDT - Market open
Market Cap160.79M
Revenue (ttm)246,000
Net Income (ttm)-57.27M
Shares Out52.05M
EPS (ttm)-1.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume139,241
Open3.15
Previous Close3.18
Day's Range3.15 - 3.23
52-Week Range1.78 - 5.11
Beta1.71
AnalystsBuy
Price Target10.00 (+212.5%)
Est. Earnings DateNov 4, 2021

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumo...

IndustryBiotechnology
CEOAoife Brennan
Employees72
Stock ExchangeNASDAQ
Ticker SymbolSYBX
Full Company Profile

Financial Performance

In 2020, Synlogic's revenue was $545,000, a decrease of -75.49% compared to the previous year's $2.22 million. Losses were -$59.17 million, 15.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 212.50% from the latest price.

Price Target
$10.00
(212.50% upside)
Analyst Consensus: Buy

News

Synlogic Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of ...

1 day ago - PRNewsWire

Synlogic Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has com...

1 day ago - PRNewsWire

Why Are Synlogic Shares Moving Higher Premarket Monday?

Synlogic Inc (NASDAQ: SYBX) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is characterize...

4 days ago - Benzinga

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phen...

CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive ...

4 days ago - PRNewsWire

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it w...

2 weeks ago - PRNewsWire

Synlogic Presents at Global PKU Patient Meeting

CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the de...

2 weeks ago - PRNewsWire

Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Synlogic Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial r...

1 month ago - PRNewsWire

Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company...

1 month ago - PRNewsWire

Will Synlogic, Inc. (SYBX) Report Negative Q2 Earnings? What You Should Know

Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platf...

CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the public...

2 months ago - PRNewsWire

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

2 months ago - Zacks Investment Research

Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketon...

CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it ha...

2 months ago - PRNewsWire

Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy

Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic medicine for inflammatory bowel disease (IBD). Un...

3 months ago - Benzinga

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

CAMBRIDGE, Mass., June 17, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it ha...

3 months ago - PRNewsWire

Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB88...

CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the dev...

3 months ago - PRNewsWire

Synlogic Reminds Stockholders of 2021 Annual General Meeting Details

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that i...

3 months ago - PRNewsWire

Synlogic to Present at Upcoming Virtual Banking and Industry Conference

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife ...

3 months ago - PRNewsWire

Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Di...

CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an ...

4 months ago - PRNewsWire

Synlogic Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial re...

4 months ago - PRNewsWire

Synlogic Announces First Quarter 2021 Conference Call & Webcast

CAMBRIDGE, Mass., May 6, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company ...

4 months ago - PRNewsWire

3 Penny Stocks That Wall Street Wants You To Buy Now

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

Other symbols:ABEOFBIO
5 months ago - Benzinga

7 Penny Stocks That May Not Be Penny Stocks For Long

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

5 months ago - InvestorPlace

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...

Other symbols:EVGNPAVMSVRA
5 months ago - PennyStocks

Synlogic Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of i...

5 months ago - PRNewsWire